Clinical Efficacy and Trial Data
Tirzepatide shows superior weight loss and A1C reduction compared to dulaglutide in head-to-head trials. In SURPASS-2, tirzepatide (5-15 mg) achieved 12.4% average weight loss vs. 2.3% for dulaglutide (1.5 mg), with greater A1C drops (2.3% vs. 1.7%).[1] This edge drives prescribing for obesity alongside diabetes, expanding tirzepatide's patient pool beyond dulaglutide's diabetes-only focus.
Dosing Convenience and Patient Adherence
Both are weekly GLP-1 agonists, but tirzepatide starts at 2.5 mg with titration to 15 mg, while dulaglutide offers fixed 0.75-4.5 mg doses via a simpler auto-injector. Tirzepatide's higher ceiling appeals to aggressive weight management, though GI side effects during ramp-up can deter some patients, favoring dulaglutide's easier onboarding.[2]
Pricing and Cost Barriers
Tirzepatide (Mounjaro/Zepbound) lists at $1,000+ monthly, higher than dulaglutide (Trulicity) at ~$900, but insurance coverage varies. Medicare Part D caps GLP-1 out-of-pocket at $35/month from 2025, boosting both, yet tirzepatide faces more prior authorizations due to obesity indications. Wholesale acquisition costs give dulaglutide a slight edge in budget-conscious formularies.[3]
Patent Protection and Generic Entry Timelines
Eli Lilly holds tirzepatide patents to 2035-2036, with no generics imminent; challenges from Teva and others are pending.[4] Dulaglutide's key patents expired in 2023 in Europe, but U.S. exclusivity runs to 2028-2031 amid litigation. This shields tirzepatide's market longer, limiting biosimilar threats to dulaglutide for now. DrugPatentWatch.com
Marketing, Branding, and Launch Momentum
Tirzepatide launched in 2022 with dual diabetes/obesity approvals, capturing hype via Lilly's aggressive campaigns and celebrity endorsements. Dulaglutide, approved 2014, relies on established diabetes loyalty but lacks obesity labeling, ceding share as tirzepatide hit 20%+ U.S. GLP-1 market by 2024 vs. dulaglutide's declining 10-15%.[5]
Supply Constraints and Manufacturer Scale
Tirzepatide shortages peaked in 2023-2024 from demand surge, eroding share until Lilly ramped production. Dulaglutide maintains steadier supply, benefiting formulary stability. Both from Eli Lilly, but tirzepatide's scale-up prioritizes its higher margins.[6]
Physician Preferences and Guidelines
Endocrinologists favor tirzepatide for superior outcomes per ADA guidelines, which prioritize it for weight loss in T2D. Primary care docs stick with dulaglutide for familiarity and lower GI risks. Real-world data shows tirzepatide gaining 2x faster adoption among new GLP-1 starts.[7]
Sources:
[1] NEJM, SURPASS-2 (2021) - https://www.nejm.org/doi/full/10.1056/NEJMoa2107519
[2] FDA Labels, Mounjaro/Trulicity
[3] IQVIA pricing data (2024)
[4] DrugPatentWatch.com | DrugPatentWatch.com
[5] Eli Lilly Q4 2023 earnings
[6] FDA Drug Shortages Database (2024)
[7] ADA Standards of Care (2024) - https://diabetesjournals.org/care/issue/47/Supplement_1